Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Advanced biomarker discovery for earlier diagnosis and improved prognosis of NAFLD stages via high resolution mass spectrometry.

Project description

Novel biomarkers for liver disease

Non-alcoholic fatty liver disease (NAFLD) affects a significant portion of the global adult population, and unless treated at an early stage, it can progress to severe conditions like non-alcoholic steatohepatitis, cirrhosis, and liver cancer. Currently, diagnosing NAFLD stages involves invasive and costly liver biopsies, highlighting the need for blood-based biomarkers for routine clinical use. Funded by the HORIZON programme, the RENAISSANCE project aims to discover such biomarkers using advanced liquid chromatography-high resolution mass spectrometry. This will involve metabolomics and exosomes analysis from a carefully characterised NAFLD patient group. Overall, RENAISSANCE has the potential to uncover new diagnostic and prognostic markers and shed light on disease mechanisms.

Objective

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of nearly 25% i.e. affects one quarter of the adult population. Early phase NAFLD is reversible and can be treated, but it may progress towards life-threatening stages such as non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). The conventional diagnosis of NAFLD stages requires liver biopsy and is time-consuming and costly and there is an urgent need to identify biomarkers that can be applied in routine clinical settings, such as through blood-based testing. The identification of blood biomarkers would support earlier diagnosis and improved assessment of prognosis, ultimately supporting preventive/intervention measures to avoid progression to late stage liver disease and thus saving lives. In RENAISSANCE, a state-of-the-art liquid chromatography-high resolution mass spectrometry (LC-HRMS) metabolomics screening will be conducted upon the blood and blood-derived exosomes of a unique deeply phenotyped cohort of NAFLD patients for molecular biomarker discovery. Notably, exosome analysis shows promise for the identification of novel disease signatures but has yet to be applied to characterize NAFLD, providing high potential for the identification of new diagnostic/prognostic biomarkers for NAFLD. Furthermore, the LC-HRMS screen will be supported via targeted assays of redox metabolites and protein markers of acute inflammation. The integration of non-target and target data will provide insight into the underlying mechanisms of disease progression and further knowledge about potential causative factors of NAFLD.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-WIDERA-2022-TALENTS-04

See all projects funded under this call

Coordinator

Masarykova univerzita
Net EU contribution
€ 150 438,72
Address
Zerotinovo namesti 9
601 77 Brno
Czechia
Region
Česko Jihovýchod Jihomoravský kraj
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data